COMMUNITY

ÃÖ°íÀÇ ±â¼ú·Â°ú ÃÖ»óÀÇ Ç°Áú,
ÂøÇÑ °¡°ÝÀ¸·Î º¸´äÇÏ¿© µå¸®°Ú½À´Ï´Ù.

Ä¿¹Â´ÏƼ
Community

  • Ȩ
  • Ä¿¹Â´ÏƼ
  • ÇÁ·Î¸ð¼Ç

ÇÁ·Î¸ð¼Ç

ÇÑÁ¤±â°£ ¾Æ¹Ù¹ÙÀÌ¿À Á¦°øÇϴ Ưº°ÇÑ °¡°Ý
Á¦¸ñ [MedChemExpress] New Small Molecules for September 2021
ÀÛ¼ºÀÚ abbabio
ÀÛ¼ºÀÏÀÚ 2021-09-06
Á¶È¸¼ö 446
MedChemExpress-Master of Small Molecules (Inhibitors, Agonists, Screening Libraries)
MedChemExpress - New Products May 2021
MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel bioactive compounds, dye reagents, peptides and natural compounds for laboratory and scientific use.
•  Over 30,000 bioactive molecules in stock
•  Target 500+ key proteins in 20+ signaling pathways
•  Quality reports (LC/MS, NMR and HPLC) for each product
•  Release more than 500 of the newest biochemicals per month
•  Data sheet with detailed biological information
•  High purity & competitive prices
•  Delivery within 24 hours

CAS No.: 315698-36-3

MLS1547

Research Area: Dopamine Receptor/ Neurological Disease

mls1547 structure
Highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (Ki=1.2 ¥ìM ).
Stimulates D2R G protein-mediated signaling (EC50=0.37 ¥ìM in a calcium mobilization assay) and acts as an antagonist for dopamine (DA)-stimulated ¥â-arrestin recruitment to the D2R.

Solubility: DMSO : 50 mg/mL (140.91 mM; Need ultrasonic)

CAS No.: 155428-00-5

Alniditan dihydrochloride

Research Area: 5-HT Receptor/Migraine

alniditan-dihydrochloride structure
Potent 5-HT1B and 5-HT1D receptors agonist with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and 5-HT1D receptors, respectively.
Has migraine-preventive effects.

Solubility: DMSO : 62.5 mg/mL (166.52 mM; Need ultrasonic)

CAS No.: 1805789-54-1

Samuraciclib hydrochloride

Research Area: CDK7 Inhibitor/Breast Cancer

samuraciclib-hydrochloride structure
Potent, selective, ATP-competitive and orally active CDK7 inhibitor (IC50=41 nM).
Displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2, CDK5 and CDK9, respectively.
Inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM and induces apoptosis.
Solubility:  DMSO : 100 mg/mL (232.03 mM; Need ultrasonic)
 H2O : 55 mg/mL (127.62 mM; Need ultrasonic)

CAS No.: 1929519-13-0

TAK-041

Research Area: GPR139/Schizophrenia

tak-041 structure
Potent and selective GPR139 agonist with an EC50 of 22 nM.
Has the potential for the research of negative symptoms associated with schizophrenia.

Solubility: DMSO : 100 mg/mL (254.89 mM; Need ultrasonic)

CAS No.: 169939-94-0
Ruboxistaurin

Research Area: PKC/Diabetic Peripheral Neuropathy

ruboxistaurin structure
Orally active, selective PKC beta (PKC¥â) inhibitor (Ki=2 nM) and inhibits the PKC beta I (IC50=4.7 nM) and PKC beta II (IC50=5.9 nM) isozymes.
Exhibits ATP dependent competitive inhibition of PKC beta I and is selective for PKC in comparison to other ATP dependent kinases (protein kinase A, calcium calmodulin, casein kinase, src tyrosine kinase).

Solubility: DMSO : 50 mg/mL (106.71 mM; ultrasonic and warming to 60¡ÆC)

CAS No.: 1414976-20-7

Vazegepant hydrochloride

Research Area: CGRP Receptor/Migraine/COVID-19

vazegepant-hydrochloride structure
High affinity antagonist of the CGRP receptor (hCGRP Ki=0.023 nM) and the first intranasal gepant for migraine.
Has the potential for the research of the COVID-19 associated pulmonary inflammation.
Solubility:  DMSO : 50 mg/mL (74.05 mM; Need ultrasonic)
 H2O : 50 mg/mL (74.05 mM; Need ultrasonic)
Renilla-Firefly Luciferase Dual Assay Kit
MCE Renilla-Firefly Luciferase Dual Assay Kit contains high-purity D-Luciferin, coelenterazine and proprietary reaction buffer. This product is ideal for the detection of both Firefly luciferase and Renilla luciferase in mammalian cells.
Antibody-drug conjugate (ADC)
Antibody-drug conjugate (ADC), a chimeric or humanized monoclonal antibody tethered to a highly potent drug (payload) through a cleavable or non-cleavable linker, is an emerging novel class of anticancer drugs and has great potential to make a paradigm shift in cancer chemotherapy. The key factors to design antibody-drug conjugates are the rational selections of payload, linker or drug-linker conjugate, antibody, and conjugation strategy.
MCE can provide one-stop services for the design, synthesis, analysis, purification, optimization, detection and evaluation of 900+ ADC-related products (ADC Cytotoxin, ADC Linker, Drug-Linker Conjugates for ADC, and ADC).
Product CategoriesService CategoriesOur Advantages
ADC CytotoxinCustom synthesisExtensive product categories
ADC LinkerConjugation service Strong synthesis ability
Drug-linker Conjugate for ADCPurification serviceInnovation ability
Antibody-drug Conjugate (ADC)Analysis serviceExtensive cooperation
Recent Publications Citing Use of MCE Products
Nature. 2021 May;593(7859):418-423.
Nature. 2021 Aug;596(7871):
291-295.
Science. 2021 Apr 30;372(6541):eaba8490.
Science. 2021 Jul 30;
373(6554):547-555.
Nat Nanotechnol. 2021 May 6.
Cell.2021 Jul 22;184(15):
4032-4047.e31.
Nat Methods. 2021 May;18(5):528-541.
Immunity. 2021 Aug 10;54(8):
1728-1744.e7.
Cell Signaling Pathway
MCE USA
Tel: 609-228-6898
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
MCE Europe
Tel: +4686500910
Address: Bergkällavägen 37C 192 79 Sollentuna SWEDEN
÷ºÎÆÄÀÏ